Staple drugs, new treatments and roles hope to solve Asthma's

Southwick, Karen
June 1998
Managed Healthcare;Jun98, Vol. 8 Issue 6, p44
Trade Publication
Discusses the effectiveness of the drugs for the treatment of asthma. Number of people in the United States died from asthma annually; Effectiveness of the anti-leukotrienes; Price of the drug.


Related Articles

  • Montelukast is Effective for Chronic Asthma ...  // Modern Medicine;Oct98, Vol. 66 Issue 10, p49 

    Discusses the abstract of the article `Montelukast, a once daily leukotriene receptor antagonist, in the treatment of chronic asthma: A multicenter, randomized, double-blind trial,' by T.F. Reiss, P. Chervinsky et al, published in the June 8, 1998 issue of the `Archives of Internal Medicine'...

  • ... And Wards Off Exercise-induced Asthma.  // Modern Medicine;Oct98, Vol. 66 Issue 10, p50 

    Discusses the abstract of the research article `Montelukast, a leukotriene-receptor antagonist for the treatment of mild asthma and exercise-induced bronchoconstriction,' by J.A. Leff, W.W. Busse et al, published in the July 16, 1998 issue of the `New England Journal of Medicine' periodical.

  • Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. Lofdahl, Claes-Goran // BMJ: British Medical Journal (International Edition);07/10/99, Vol. 319 Issue 7202, p87 

    Presents information on a study on the ability of montelukast, a leukotriene receptor antagonist, to allow tapering of inhaled corticosteroids in clinically stable asthmatic patients. Participants and methods; Results; Conclusions.

  • Pranlukast dry syrup inhibits symptoms of Japanese cedar pollinosis in children using OHIO Chamber. Wakabayashi, Ken-ichiro; Hashiguchi, Kazuhiro; Kanzaki, Sho; Fujioka, Masato; Tanaka, Nobuaki; Kawashima, Kayoko; Suematsu, Kiyochika; Yamamotoya, Hajime; Iwasaki, Manabu; Gotoh, Minoru; Horibe, Seiji; Naito, Kensei; Okubo, Kimihiro // Allergy & Asthma Proceedings;Jan/Feb2012, Vol. 33 Issue 1, p102 

    Pranlukast (PLK) is a leukotriene receptor antagonist (LTRA) that has been approved for treatment of asthma in patients of all ages and allergic rhinitis (AR) in adults but not for AR in children in Japan. This randomized, double-blind, placebo-controlled, crossover study used an artificial...

  • Modern drug treatment of chronic asthma. Lipworth, Brian J // BMJ: British Medical Journal (International Edition);02/06/99, Vol. 318 Issue 7180, p380 

    Provides a brief overview of modern drug treatment for chronic asthma. Corticosteroids; Cromones; Leukotriene antagonists.

  • Leukotriene inhibitors shown to improve asthma patients. Rodgers, Katie // Drug Topics;4/10/95, Vol. 139 Issue 7, p27 

    Reports that leukotriene inhibitors have been shown to improve asthma symptoms and pulmonary functions. Presentation of evidence of zileuton's therapeutic usefulness at the 1995 International Conference of the American Academy of Allergy and Immunology; Improvements noted in patients treated...

  • Recently approved leukotriene cuts the number of days with symptoms and the number of physician...  // Modern Medicine;Apr97, Vol. 65 Issue 4, p16 

    Reports on the effectiveness of a daily regimen of zafirlukast, a leukotriene receptor antagonist, in combination with an as-needed beta agonist in treating patients with mild-to-moderate asthma. Decline in the number of days in which the patients experienced asthmatic symptoms; Decline in the...

  • Focus on zafirlukast: A leukotriene receptor antagonist for the prophylaxis and chronic... Baldinger, Sandra L.; Shore, Eric T. // Formulary;Nov96, Vol. 31 Issue 11, p1029 

    Examines the use and effectiveness of zafirlukast, a potent and specific leukotriene receptor antagonist approved by the Food and Drug Administration (FDA) for the treatment of asthma in patients 12 years of age and older. Chemistry and pharmacology; Pharmacokinetics; Results of clinical trials...

  • Defining the role of antileukotriene agents in the management of asthma. Johnson, Margaret M. // Formulary;Jan2000, Vol. 35 Issue 1, p38 

    The newest class of asthma medications to be marketed in the United States are the antileukotriene agents (ALAs). They include one 5-lipoxygenase inhibitor, zileuton, and two leukotriene receptor antagonists, zafirlukast and montelukast. By inhibiting the formation of cysteinyl leukotrienes or...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics